Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now? Beloud

@fool.com · 1 hour

Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?

Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?

Novo Nordisk's weight-loss drug Wegovy is significantly outperforming market expectations, fueling intense competition with Eli Lilly in the GLP-1 sector. As the pharmaceutical giant continu...

Read more Fool.com